Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epalrestat + PARPi rechallenge maintenance in platinum-sensitive recurrent ovarian cancer after prior PARPi
ChiCTR2600130178Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epalrestat in ovarian cancer, sponsored by Hunan Cancer Hospital. Primary endpoint: 6-month progression-free survival rate. Started Aug 2026; status: recruiting.
02
Drugs
epalrestat
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2600130178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130178.